Bristol-Myers Squibb

Go or no go? Covid-19 upstages US regulatory decisions
EP Vantage
Tue, 03/24/20 - 10:30 am
FDA
regulatory
Bristol-Myers Squibb
ozanimod
Esteve
E-58425
Fabre-Kramer
AstraZeneca
Imfinzi
Astellas
Vesicare
AbbVie
Neurocrine
Orlissa
Sanofi
MenQuadfi
opicapone
Acceleron
Reblozyl
Janssen files MS pill, ahead of FDA decision on BMS’ rival
Pharmaforum
Thu, 03/19/20 - 11:06 am
Janssen
JNJ
multiple sclerosis
MS
FDA
ponesimod
Bristol-Myers Squibb
ozanimod
Bristol Myers CEO Caforio hires a top investment banker from Barclays for his next BD/strategy chief
Endpoints
Wed, 03/18/20 - 10:18 am
Bristol-Myers Squibb
M&A
Giovanni Caforio
With Bristol and Otsuka on Board, LSP Raises $620M EU Life Sciences Fund
Xconomy
Wed, 03/11/20 - 07:26 pm
LSP
life sciences
Bristol-Myers Squibb
Otsuka
Europe
Bristol Myers Squibb snags new liver cancer nod for Opdivo-Yervoy combo
Fierce Pharma
Wed, 03/11/20 - 12:58 pm
Bristol-Myers Squibb
Opdivo
Yervoy
FDA
liver cancer
hepatocellular carcinoma
2 newer multiple myeloma drugs fall short in bid for wider market
BioPharma Dive
Tue, 03/10/20 - 11:58 am
Multiple Myeloma
clinical trials
Bristol-Myers Squibb
Takeda
Ninlaro
Empliciti
Revlimid
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
BioSpace
Mon, 03/9/20 - 11:10 pm
biosimilars
Amgen
Allergan
Roche
Rituxan
Bristol-Myers Squibb
ozanimod
risdiplam
Biomarin
valrox
Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy
Endpoints
Mon, 03/9/20 - 10:52 am
Bristol-Myers Squibb
Celgene
M&A
clinical trials
Multiple Myeloma
Empliciti
AbbVie
Revlimid
Big Pharma grounds employees: GSK, Bristol, Roche, Sanofi and more limit travel due to coronavirus
Fierce Pharma
Fri, 03/6/20 - 11:27 pm
COVID-19
coronaviruses
Roche
GSK
Bristol-Myers Squibb
Sanofi
Boehringer Ingelheim
Amgen
Biogen
Mylan
BMS joins with Voluntis to create cancer support app
Pharmaforum
Thu, 03/5/20 - 11:01 am
Bristol-Myers Squibb
Voluntis
cancer
mobile apps
Bristol Myers Squibb unveils new branding, will phase out Celgene brand
Medical Marketing and Media
Thu, 03/5/20 - 10:27 am
Bristol-Myers Squibb
Celgene
rebranding
M&A
Bristol-Myers Squibb reaches tentative deal to end long-running Medicaid rebate lawsuit
Fierce Pharma
Fri, 02/28/20 - 11:55 pm
Bristol-Myers Squibb
Medicaid
Go or no go? Ozanimod and Fintepla await FDA verdicts
EP Vantage
Wed, 02/26/20 - 10:26 am
Bristol-Myers Squibb
ozaminod
MS
multiple sclerosis
Zogenix
Fintepla
FDA
Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease
Motley Fool
Sun, 02/23/20 - 06:17 pm
beta thalassemia
rare disease
drug development
Acceleron
Bristol-Myers Squibb
Bluebird Bio
Sangamo Therapeutics
Vertex Pharmaceuticals
Editas Medicine
Syros Pharmaceuticals
A Big Month Ahead for the FDA and Bristol-Myers Squibb
Motley Fool
Sat, 02/22/20 - 11:39 pm
Bristol-Myers Squibb
Celgene
FDA
ozanimod
Opdivo
Reblozyl
Five Prime Therapeutics’ pancreatic cancer combo with Opdivo a bust
Fierce Biotech
Tue, 02/18/20 - 08:29 pm
Five Prime Therapeutics
cabiralizumab
Bristol-Myers Squibb
Opdivo
pancreatic cancer
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
Mon, 02/17/20 - 11:33 pm
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Opdivo delivers superior five-year survival results in renal cell carcinoma
Pharmaceutical Business Review
Mon, 02/17/20 - 10:33 am
Bristol-Myers Squibb
Opdivo
clinical trials
renal cell carcinoma
Bristol-Myers' CAR-T gets priority review, mid-August PDUFA date
Fierce Biotech
Thu, 02/13/20 - 11:04 am
Bristol-Myers Squibb
FDA
lisocabtagene maraleucel
priority review
CAR-T
Biotech Q4 Earnings Synopsis: Major Restructuring and Overall Growth Are Themes
BioSpace
Mon, 02/10/20 - 10:19 am
earnings
Bristol-Myers Squibb
AbbVie
Novo Nordisk
Merck
GSK
Seattle Genetics

Pages